Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
Launched by WARNER CHILCOTT · Jun 16, 2008
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
The data to support the interchangeability of one risedronate 150 mg tablet versus two risedronate 75 mg tablets as monthly dose forms is primarily based on the similarity of in vitro dissolution and an in vivo study, which showed risedronate absorption is not dissolution rate limited. These results suggest that monthly dosing of risedronate may be accomplished by administration of either one risedronate 150 mg tablet or two risedronate 75 mg tablets. The purpose of this study is to provide additional clinical data to support the interchangeability of these 2 dose regimens.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • be in good general health based on medical history, physical examination, and laboratory evaluation
- • have a body mass index (BMI) ≤ 32 kg/m2 at screening
- Exclusion Criteria:
- • has clinically significant uncontrolled cardiovascular, hepatic, renal, or thyroid disease
- • has any disease or surgery known to alter normal GI structure or function
- • has a creatinine clearance of \< 60 mL/min, estimated by serum creatinine using the Cockcroft-Gault formula
About Warner Chilcott
Warner Chilcott is a leading pharmaceutical company specializing in the development and commercialization of innovative prescription products in the fields of women's health, urology, and dermatology. With a commitment to enhancing patient outcomes, Warner Chilcott focuses on delivering high-quality medications that meet the evolving needs of healthcare providers and patients. The company is dedicated to rigorous clinical research and adherence to regulatory standards, ensuring the safety and efficacy of its therapies. Through strategic partnerships and a robust pipeline, Warner Chilcott continues to advance healthcare solutions that improve the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gainesville, Florida, United States
Miramar, Florida, United States
Austin, Texas, United States
Dallas, Texas, United States
Patients applied
Trial Officials
William S Aronstein, PhD/M/FACP
Study Director
Procter and Gamble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials